Advertisement Pharmaceutical Business review - Page 149 of 5258 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 22, 2026

Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis

Opna Bio has received the US Food and Drug Administration’s (FDA) orphan drug designation for OPN-2853 (zavabresib), a bromodomain and extra-terminal motif (BET) small molecule inhibitor, to treat myelofibrosis.

Continue
Myelofibrosis is a rare blood cancer causing bone marrow scarring, severe fatigue, anaemia, and enlarged spleen. Credit: Nemes Laszlo / Shutterstock.com.
January 22, 2026

Johnson & Johnson reports 9.1% increase in sales for Q4 2025

J&J forecasts 2026 sales of $100.5bn and adjusted EPS of $11.53 at the midpoint. Credit: PixelBiss / Shutterstock.com.
January 20, 2026

DeepHow introduces PharmaCloud for pharmaceutical manufacturers

PharmaCloud maintains traceability, governance, and controls necessary to comply with GMP requirements. Credit: ART STOCK CREATIVE / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. BMS and Microsoft partner for AI-based lung cancer detection
  2. Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies
  3. iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s
  4. AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy
  5. FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease

PRESS RELEASES

SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Pharmaceutical Business Review
Christian Mias to Succeed Andreas Reisse as CEO of SCHOTT Pharma
Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography